RU2009144280A - АНТАГОНИСТЫ CRIg - Google Patents
АНТАГОНИСТЫ CRIg Download PDFInfo
- Publication number
- RU2009144280A RU2009144280A RU2009144280/10A RU2009144280A RU2009144280A RU 2009144280 A RU2009144280 A RU 2009144280A RU 2009144280/10 A RU2009144280/10 A RU 2009144280/10A RU 2009144280 A RU2009144280 A RU 2009144280A RU 2009144280 A RU2009144280 A RU 2009144280A
- Authority
- RU
- Russia
- Prior art keywords
- crig
- antibody
- antagonist
- fragment
- atcc
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title claims abstract 34
- 101000743488 Homo sapiens V-set and immunoglobulin domain-containing protein 4 Proteins 0.000 claims abstract 39
- 102100038296 V-set and immunoglobulin domain-containing protein 4 Human genes 0.000 claims abstract 39
- 239000012634 fragment Substances 0.000 claims abstract 18
- 244000052769 pathogen Species 0.000 claims abstract 13
- 230000001717 pathogenic effect Effects 0.000 claims abstract 13
- 230000003834 intracellular effect Effects 0.000 claims abstract 8
- 241000700605 Viruses Species 0.000 claims abstract 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract 4
- 241000894006 Bacteria Species 0.000 claims abstract 3
- 230000000295 complement effect Effects 0.000 claims abstract 3
- 230000001419 dependent effect Effects 0.000 claims abstract 3
- 230000001404 mediated effect Effects 0.000 claims abstract 3
- 244000045947 parasite Species 0.000 claims abstract 3
- 230000035515 penetration Effects 0.000 claims abstract 3
- 108010078015 Complement C3b Proteins 0.000 claims abstract 2
- 229920001184 polypeptide Polymers 0.000 claims abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 2
- 241000124008 Mammalia Species 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 claims 2
- 241000233866 Fungi Species 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 241000701806 Human papillomavirus Species 0.000 claims 2
- 102000029797 Prion Human genes 0.000 claims 2
- 108091000054 Prion Proteins 0.000 claims 2
- 241000700584 Simplexvirus Species 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91534007P | 2007-05-01 | 2007-05-01 | |
| US60/915,340 | 2007-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009144280A true RU2009144280A (ru) | 2011-06-10 |
Family
ID=39645433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009144280/10A RU2009144280A (ru) | 2007-05-01 | 2008-04-25 | АНТАГОНИСТЫ CRIg |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20090162356A1 (enExample) |
| EP (1) | EP2152749A1 (enExample) |
| JP (1) | JP2010526076A (enExample) |
| KR (1) | KR20100018523A (enExample) |
| CN (1) | CN101675078A (enExample) |
| AR (1) | AR066375A1 (enExample) |
| AU (1) | AU2008247958A1 (enExample) |
| BR (1) | BRPI0810926A2 (enExample) |
| CA (1) | CA2682835A1 (enExample) |
| CL (1) | CL2008001238A1 (enExample) |
| IL (1) | IL201165A0 (enExample) |
| MX (1) | MX2009011407A (enExample) |
| PE (1) | PE20090239A1 (enExample) |
| RU (1) | RU2009144280A (enExample) |
| WO (1) | WO2008137338A1 (enExample) |
| ZA (1) | ZA200906812B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2826236C1 (ru) * | 2019-09-04 | 2024-09-06 | Уай-БИОЛОДЖИКС ИНК. | Антитело против vsig4 или его антигенсвязывающий фрагмент и их применение |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
| LT2280996T (lt) * | 2008-05-06 | 2016-12-12 | Genentech, Inc. | Subrendusio giminingumo crig variantai |
| US8241623B1 (en) | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
| US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
| US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
| CN104231085B (zh) * | 2013-09-05 | 2017-03-15 | 复旦大学附属肿瘤医院 | 靶向特异性补体系统抑制剂、其制备方法及应用 |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CN105924515B (zh) * | 2016-04-25 | 2019-06-14 | 中国人民解放军第三军医大学 | 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用 |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US10752689B2 (en) * | 2017-06-26 | 2020-08-25 | Bio-Techne Corporation | Hybridoma clones, monoclonal antibodies to VSIG-4, and methods of making and using |
| KR102857892B1 (ko) * | 2018-09-28 | 2025-09-10 | 주식회사 유틸렉스 | 항-인간 vsig4 항체 및 이의 용도 |
| WO2020236626A1 (en) * | 2019-05-17 | 2020-11-26 | Herzlinger George A | Methods and systems for treating microbial disease |
| MX2022002672A (es) * | 2019-09-04 | 2022-06-16 | Y Biologics Inc | Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo. |
| KR20230156727A (ko) | 2021-03-03 | 2023-11-14 | 피에르 파브르 메디카먼트 | 항-vsig4 항체 또는 이의 항원 결합 단편 및 용도 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8088386B2 (en) * | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
-
2008
- 2008-04-25 AU AU2008247958A patent/AU2008247958A1/en not_active Abandoned
- 2008-04-25 MX MX2009011407A patent/MX2009011407A/es active IP Right Grant
- 2008-04-25 KR KR1020097024920A patent/KR20100018523A/ko not_active Withdrawn
- 2008-04-25 EP EP08769166A patent/EP2152749A1/en not_active Withdrawn
- 2008-04-25 JP JP2010506507A patent/JP2010526076A/ja active Pending
- 2008-04-25 RU RU2009144280/10A patent/RU2009144280A/ru not_active Application Discontinuation
- 2008-04-25 BR BRPI0810926-5A2A patent/BRPI0810926A2/pt not_active IP Right Cessation
- 2008-04-25 CA CA002682835A patent/CA2682835A1/en not_active Abandoned
- 2008-04-25 CN CN200880014866A patent/CN101675078A/zh active Pending
- 2008-04-25 WO PCT/US2008/061513 patent/WO2008137338A1/en not_active Ceased
- 2008-04-25 US US12/150,220 patent/US20090162356A1/en not_active Abandoned
- 2008-04-30 CL CL2008001238A patent/CL2008001238A1/es unknown
- 2008-04-30 PE PE2008000774A patent/PE20090239A1/es not_active Application Discontinuation
- 2008-04-30 AR ARP080101847A patent/AR066375A1/es not_active Application Discontinuation
-
2009
- 2009-09-24 IL IL201165A patent/IL201165A0/en unknown
- 2009-09-30 ZA ZA2009/06812A patent/ZA200906812B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2826236C1 (ru) * | 2019-09-04 | 2024-09-06 | Уай-БИОЛОДЖИКС ИНК. | Антитело против vsig4 или его антигенсвязывающий фрагмент и их применение |
Also Published As
| Publication number | Publication date |
|---|---|
| AR066375A1 (es) | 2009-08-12 |
| IL201165A0 (en) | 2010-05-17 |
| KR20100018523A (ko) | 2010-02-17 |
| AU2008247958A1 (en) | 2008-11-13 |
| PE20090239A1 (es) | 2009-03-19 |
| CA2682835A1 (en) | 2008-11-13 |
| MX2009011407A (es) | 2009-11-05 |
| US20090162356A1 (en) | 2009-06-25 |
| EP2152749A1 (en) | 2010-02-17 |
| JP2010526076A (ja) | 2010-07-29 |
| BRPI0810926A2 (pt) | 2014-11-04 |
| CL2008001238A1 (es) | 2008-11-07 |
| CN101675078A (zh) | 2010-03-17 |
| WO2008137338A1 (en) | 2008-11-13 |
| ZA200906812B (en) | 2010-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009144280A (ru) | АНТАГОНИСТЫ CRIg | |
| JP2010526076A5 (enExample) | ||
| Lanzavecchia et al. | Human monoclonal antibodies by immortalization of memory B cells | |
| RU2462475C2 (ru) | Антитела против вируса гепатита с | |
| RU2012142230A (ru) | Антитела против csf-1r человека и их применение | |
| JP2011527902A5 (enExample) | ||
| RU2012142231A (ru) | Антитела против csf-1r человека и их применение | |
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| JP2017536341A5 (enExample) | ||
| RU2020115527A (ru) | Биспецифичные молекулы, иммунореактивные с иммунными эффекторными клетками, экспрессирующими активирующий рецептор | |
| PE20141398A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| CA2963470A1 (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| CN107667115A (zh) | 针对埃博拉病毒糖蛋白的人抗体 | |
| JP2011527899A5 (enExample) | ||
| RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| RU2010100638A (ru) | Композиции и способы лечения, направленные против cd20 | |
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| JP2018520334A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2014127438A (ru) | Антитела против человеческого csf-1r и их применения | |
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| RU2014127287A (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
| JP2021500916A5 (enExample) | ||
| RU2018100824A (ru) | Антитела, которые связываются с сортилином и подавляют связывание програнулина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130605 |